Recently, Zhejiang Hengkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Hengkang Pharm") signed relevant agreements with Meiji Seika Pharma Co., Ltd. and other companies. Hengkang Pharm completed the acquisition of 100% shares of Meiji Pharma (Shandong) Co., Ltd., which is the subsidiary of Meiji Seika Pharma and changed its name to Nugene Pharma (Shandong) Co., Ltd..

This transaction will lay a solid foundation for further expanding the product line of Hengkang Pharm and consolidating the industrial layout of pharmaceutical raw materials.

Meiji Seika Pharma is one of the members of The Meiji Group, a well-known group of consolidated companies with a long history in the Japanese food industry and pharmaceutical industry. Their products cover dairy products, candy, and nutritional products, which are deeply loved by consumers, as well as pharmaceuticals. Meiji Seika Pharma is committed to research and development, production and sales of vaccines and, antibacterial drugs for infectious diseases, central nervous system drugs and generic drugs, etc., having a high-standard quality management system and enjoys a high reputation in the industry.

Hengkang Pharm is a pharmaceutical enterprise covering front-end research and development of pharmaceutical intermediates, key raw materials, high-end preparations and biomolecular building blocks to large-scale production and global marketing. It is committed to providing customers with high-quality pharmaceutical raw materials and professional services. Official inspections by domestic and foreign food and drug administrations, such as China's NMPA, EU's EDQM, Japan's PMDA, Korea's KFDA, etc., have successively obtained CEP certificates for multiple core APIs products.

Through this acquisition, Hengkang Pharm has achieved a new layout of the company's business, quickly entered the field of synthetic biology, improved the commercial production capacity of products in the field of synthetic biology, enriched the product pipeline, and added synthetic biology CMO service capabilities. The new industrial layout continues the company's development path, continues to expand the product market and service scope, and continues to provide more and better products and services for the downstream customers of the pharmaceutical industry.